other material
confidence high
sentiment negative
materiality 0.65
Seres Therapeutics cuts workforce 25%, extends cash runway into Q2 2026
Seres Therapeutics, Inc.
- Reducing workforce by approximately 25%, including reductions effective August 2025.
- Expected cash charges of $1.0-1.4 million, primarily severance, paid in Q4 2025.
- Cash runway extended into Q2 2026 based on current operating plans and cost savings.
- Company cites need to reduce costs to advance strategic priorities amid ongoing losses.